Cure SMA is pleased to announce the involvement of scientific leadership, in the 4th Scientific International Congress on SMA (March 14 – 16, 2024), the 2024 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference (May 5 – 8, 2024), and the Annual SMA Research & Clinical Care Meeting (June 5 – 7, 2024).
Our poster presentations featured data from research initiatives launched by the Cure SMA Real World Evidence Collaboration (RWEC). The collaboration was established to leverage the experience, expertise and resources of pharmaceutical and biotechnology companies and nonprofit organizations involved in development of SMA therapeutics to guide the future direction of real world evidence collection and use in SMA. The primary goal of the Real World Evidence Collaboration is to improve the quality and volume of real world data collection in SMA.
Below is a re-cap of the RWEC posters we presented this spring.
![905092024_RWEC_Logo 1 905092024_RWEC_Logo 1](https://www.curesma.org/wp-content/uploads/2024/08/905092024_RWEC_Logo-1.png)
About the Real World Evidence Collaboration
The Cure SMA Real World Evidence Collaboration (RWEC) was established to leverage the experience, expertise and resources of pharmaceutical and biotechnology companies and nonprofit organizations involved in development of SMA therapeutics to guide the future direction of real world evidence collection and use in SMA. Funding for this research was provided by the RWEC; members include Cure SMA, Biogen, Genentech/Roche, and Novartis.